Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer

This study is testing a drug called ivonescimab — a new type of immunotherapy that combines two cancer-fighting mechanisms into one antibody — given before surgery in people with head and neck cancer that can still be removed surgically. The goal is to see whether this treatment can shrink tumors before surgery and improve outcomes. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with advanced head and neck cancer (squamous cell carcinoma, stage II–IV) that is recommended for surgery as standard care - Your tumor tests positive for PD-L1 (a protein linked to immune checkpoint activity) - You are in generally good physical health (ECOG 0 or 1) - Your blood counts, liver, and kidney function meet the required thresholds **You may NOT be eligible if...** - You have previously received radiation therapy to the area or had prior neck dissection for this cancer - You have significant bleeding tendencies or are on therapeutic blood thinners that are not stable - You have an active autoimmune disease that has required treatment in the past 5 years - You have active hepatitis B or C, or uncontrolled HIV - You have had a heart attack, stroke, or blood clot in the past 12 months - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.